PACSIN2

Across TCGA pan-cancer cohorts, PACSIN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PACSIN2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PACSIN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PACSIN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where PACSIN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.396	0.193	<.001	30	view →
GBM	DFS	Median	All	0.237	0.491	<.001	28	view →
CCRCC	OS	Tertile	III,IV	0.865	0.567	.006	18	view →
LUAD	OS	Median	II,III,IV	0.429	0.911	.008	17	view →
HNSC	OS	Median	II,III,IV	0.950	1.000	.014	7	view →
UCEC	DFS	Quartile	II,III,IV	0.846	0.326	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PACSIN2–PDAC (DFS)

Open the PDAC breakdown →